Use of Second- And Third-Generation Tyrosine Kinase Inhibitors in the Treatment of Chronic Myeloid Leukemia: An Evolving Treatment Paradigm

Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2015.03.006
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV